DC-CIK联合化疗治疗非小细胞肺癌的临床疗效评价(英文)

查看全文 作　　者：Junping [1]Zhang;Guanghua [1]Mao;Yaping [1]Han;Xiaoling [1]Yang;Huijing [1]Feng;Linzi [1]Jia;Ting [1]Zhi;Yan [1]Xiao;Libin [1]Zhang;Jiangtao [1]Wang;Tianliang [1]Shi

机构地区：[1]Department of Biotherapy,Affiliated to Cancer Hospital of Shanxi Medical University,Taiyuan 030013,China

出　　处：《The Chinese-German Journal of Clinical Oncology》索引2012年第11卷第2期,共5页

基　　金：Supported by a grant from the key Scientific Foundation of Shanxi Province (No. 051096-2) 摘　　要：Objective: The aim of the study was to evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stages III to IV), who had received therapies in our Center (Department of Biotherapy, Affiliated to Cancer Hospital of Shanxi Medical University, Taiyuan, China) from August 2008 to January 2010, were treated by DC-CIK + chemotherapy as the combined treatment group; fifty advanced NSCLC patients treated with chemotherapy at the same time served as controls. The immunologic function, short-term therapeutic effects, the 1-year survival rate, the life quality, the chemotherapy side effects were compared between the two groups, the safety and therapeutic effects of DC-CIK cells therapy were observed too. Results: There was no obvious change of subsets of T cells in peripheral blood before and after therapy in DC-CIK + chemotherapy group, and IFN-γ was improved after therapy in this group (P < 0.05); in chemotherapy alone group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and the secretion of IL-2, TNF-α decreased significantly after therapy (P < 0.05); the ratios of CD3+CD8+, CD3+CD56+ were improved after cell culture (P < 0.05). The disease control rate (DCR) of DC-CIK + chemotherapy group was higher than that in the chemotherapy alone group (78.0% vs 56.0%, P < 0.05); the 1-year survival rates of DC-CIK + chemotherapy group and chemotherapy alone group were 50% and 44% respectively, had no significant difference. Compared with chemotherapy alone group, the occurrence of chemotherapy side effects (including bone marrow suppression, nausea and vomiting, peripheral nerve toxicity) was less in the DC-CIK + chemotherapy group (P < 0.05). The physical and appetite were better in DC-CIK + chemotherapy group after therapy. Conclusion: To compare with simple chemotherapy, DC-CIK + chemotherapy for advanced NSCLC is safe and effective, and it can improve patients' life quality and remission rate, and prolong their survival time. 关键词：非小细胞肺癌生物治疗化疗晚期临床效果山西医科大学生活质量毒副作用

相关文献

参考文献（22）
引证文献（3）
耦合文献（74）

参考文献(22)

引证文献(3)

耦合文献(74)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

DC-CIK联合化疗治疗非小细胞肺癌的临床疗效评价(英文)

参考文献(22)

引证文献(3)

耦合文献(74)

用户提示